category,datetime,headline,id,image,related,source,summary,url
company,1769015100,Nation’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search,138197312,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,REGN,Yahoo,"The Regeneron Science Talent Search Honors America’s Brightest Young Scientists Advancing Discovery and Innovation Society for Science & Regeneron Announce Top 40 Science Talent Search Finalists Society for Science and Regeneron today announced the top 40 finalists in the Regeneron Science Talent Search 2026, America’s oldest and most prestigious science and math competition for high school seniors. TARRYTOWN, N.Y. and WASHINGTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Society for Science (the Societ",https://finnhub.io/api/news?id=02b7c6d0d5cdee49da7570e8845930d8498d8d7421537a7f865803900d84ae0e
company,1769013780,Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors despite daily gains,138212216,,REGN,MarketWatch,Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors despite daily gains,https://finnhub.io/api/news?id=7911e08899844412f392e56f8d1e69daa95a7986a4582b27f591fbdd25aa494e
company,1769007039,Corvus Pharmaceuticals: ITK Inhibitor Soquelitinib AD Data Could Be Improved Upon,138198106,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2242759989/image_2242759989.jpg?io=getty-c-w1536,REGN,SeekingAlpha,"Corvus Pharmaceuticals, Inc. shares are up on solid soquelitinib AD phase 1 data: 75% hit EASI 75 at 200 mg BID, many benefits, broad upside. Click for this CRVS update.",https://finnhub.io/api/news?id=e0cb69eae9c335eddda1ee9277683030abe30f4247fc28d9b0dae6a71bd4b1f0
company,1768996800,Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer,138195231,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,REGN,Yahoo,"Accomplished global commercial leader with deep expertise in retina drug launches Primary architect for the industry-defining launch of EYLEA® while at Regeneron Most recently served as Chief Marketing Officer, Global Ophthalmology at Merck BEDFORD, Mass., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that David W. Robinson has agreed to join the Company a",https://finnhub.io/api/news?id=755664a1769e9af43ddf078ad74cef05eccc85b9aa0a464581bb35553c8fca72
company,1768995540,Corvus shares nearly triple on positive data for eczema pill,138197313,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,REGN,Yahoo,"While early, the results indicate drugs known as ITK inhibitors have the potential to match or surpass the efficacy observed with the injectable biologic Dupixent.",https://finnhub.io/api/news?id=bdc7c721240401b8c933d7c580ed2ffcdf96a35edc5ec70528693fb48bab0b17
